TrialJournal of the National Cancer Institute2019

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.

Véronique Diéras et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.